Pomerantz Investigates Ultragenyx After Failed Angelman Trial
Analysis based on 7 articles · First reported Sep 08, 2026 · Last updated Sep 23, 2026
The failed Phase 3 trial and subsequent 44% stock drop have severely damaged investor confidence in Ultragenyx, and the securities investigation adds legal and reputational risk that could further pressure the stock. The event highlights the high-risk nature of clinical-stage biotech investments, potentially affecting sentiment across the sector.
Pomerantz LLP announced it is investigating claims on behalf of investors of Ultragenyx regarding potential securities fraud or other unlawful business practices. The investigation follows Ultragenyx's September 2, 2026 press release announcing results from the Phase 3 Aspire study for apazunersen (GTX-102) in Angelman syndrome. According to the press release, the study did not achieve the primary endpoint of change from Baseline in Bayley-4 cognitive raw score nor the key secondary endpoint of net response in Multidomain Responder Index (MDRI). On this news, Ultragenyx's stock price fell $11.68 per share, or 44.03%, to close at $14.85 per share on September 3, 2026. Pomerantz LLP, a law firm specializing in corporate, securities, and antitrust class litigation, is advising affected investors to contact Danielle Peyton to join the potential class action. The investigation concerns whether Ultragenyx and certain of its officers and/or directors engaged in securities fraud or other unlawful business practices.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard